Alyeska Investment Group
AKBA icon

Alyeska Investment Group’s Akebia Therapeutics AKBA Stock Holding History

Alyeska Investment Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-134,277
Closed -$258K – 549
2025
Q1 		$258K Buy
+134,277
New +$274K ﹤0.01% 484
2018
Q3 		– Sell
-97,734
Closed -$975K – 403
2018
Q2 		$975K Sell
97,734
-4,701
-5% -$47.1K 0.01% 400
2018
Q1 		$976K Sell
102,435
-925
-0.9% -$12.9K 0.01% 391
2017
Q4 		$1.54M Sell
103,360
-23,914
-19% -$397K 0.01% 356
2017
Q3 		$2.5M Buy
127,274
+2,274
+2% +$35K 0.02% 339
2017
Q2 		$1.8M Buy
+125,000
New +$1.58M 0.02% 358

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's AKBA Position: Q2 2025 in Review

Alyeska Investment Group sold out of Akebia Therapeutics (AKBA) in Q2 2025, closing a stake of 134,277 shares — an estimated $258K sold.

Alyeska Investment Group first reported a position in AKBA in Q2 2017 and held it in 6 quarters. The position peaked at $2.5M in Q3 2017. 157 funds tracked by Wall St. Rank hold AKBA as of Q2 2025.

  • Alyeska Investment Group reported no remaining Akebia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 134,277 Akebia Therapeutics shares in Q2 2025, an estimated $258K.
  • Alyeska Investment Group first reported a position in Akebia Therapeutics in Q2 2017 and held it in 6 quarters.
  • Alyeska Investment Group's Akebia Therapeutics position peaked at $2.5M in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.